Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 8/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 8/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 8/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.32 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.32 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.32 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5311913 | 0.83 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL13583919 | 0.80 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL13583918 | 0.80 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL6249367 | 0.78 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL28327923 | 0.74 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL28147764 | 0.74 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL3333900 | 0.74 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL3333899 | 0.74 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL13583338 | 0.73 | ALDH1A1 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL2820728 | 0.73 | ALDH1A1 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090053290-A1 | TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN | NUVIANCE, INC. | 2009-02-26 | — | — | US | disclosed |
| EP-0983372-A1 | IMPROVED TRANSAMINASE BIOTRANSFORMATION PROCESS | MONSANTO COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998053088-A1 | IMPROVED TRANSAMINASE BIOTRANSFORMATION PROCESS | NSC TECHNOLOGIES L.L.C. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053290-A1 | TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN | LRAT, LTA, COLGALT1 | SLC7A5 3805/4885SLC1A3 4065/4885SLC1A2 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.